MT Newswires
European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading
📊
AI Sentiment
Positive
6/10
as of 12-05-2025 4:00pm EST
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
| Founded: | 2008 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 42.7M | IPO Year: | 2021 |
| Target Price: | $12.33 | AVG Volume (30 days): | 99.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.20 - $12.15 | Next Earning Date: | 11-06-2025 |
| Revenue: | $7,650,000 | Revenue Growth: | 132.17% |
| Revenue Growth (this year): | 128.77% | Revenue Growth (next year): | -83.33% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
EVAX Breaking Stock News: Dive into EVAX Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
6/10
AI Sentiment
Neutral
5/10
See how EVAX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "EVAX Evaxion Biotech - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.